CIK 0002023658 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Bicara Therapeutics Inc.
Sign in to watch- Ticker
- BCAX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-468-4219
- Business address
- 116 HUNTINGTON AVENUE SUITE 703, BOSTON, MA, 02116
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $400,716
- in 1 filing, $401K under 10b5-1 plans
Net −$400,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-22 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 | −9,200 | $18.31 | $168K | 145,355 |
| 2025-12-22 | Hyep Ivan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −9,200 | 88,984 | ||
| 2025-12-16 | Mazumdar Claire Chief Executive Officer | Option exercise | +29,500 | $5.45 | $161K | 339,392 |
| 2025-12-16 | Mazumdar Claire Chief Executive Officer | Option exercise · Stock Option (Right to Buy) | −29,500 | 565,512 | ||
| 2025-12-15 | Cohlhepp Ryan President and COO | Option exercise 10b5-1 | +8,000 | $3.79 | $30K | 201,641 |
| 2025-12-15 | Cohlhepp Ryan President and COO | Sale 10b5-1 | −8,000 | $18.68 | $149K | 193,641 |
| 2025-12-15 | Cohlhepp Ryan President and COO | Sale 10b5-1 | −4,500 | $18.68 | $84K | 189,141 |
| 2025-12-15 | Cohlhepp Ryan President and COO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −8,000 | 141,334 | ||
| 2025-11-25 | Raben David Chief Medical Officer | Option exercise 10b5-1 | +4,594 | $3.79 | $17K | 40,091 |
| 2025-11-25 | Raben David Chief Medical Officer | Sale 10b5-1 | −4,594 | $18.84 | $87K | 35,497 |
| 2025-11-25 | Raben David Chief Medical Officer | Option exercise 10b5-1 | +906 | $3.79 | $3K | 36,403 |
| 2025-11-25 | Raben David Chief Medical Officer | Sale 10b5-1 | −906 | $18.84 | $17K | 35,497 |
| 2025-11-25 | Raben David Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,594 | 118,776 | ||
| 2025-11-25 | Raben David Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −906 | 69,413 | ||
| 2025-11-24 | Raben David Chief Medical Officer | Option exercise 10b5-1 | +5,500 | $3.79 | $21K | 40,997 |
| 2025-11-24 | Raben David Chief Medical Officer | Sale 10b5-1 | −5,500 | $18.45 | $101K | 35,497 |
| 2025-11-24 | Raben David Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,500 | 123,370 | ||
| 2025-11-24 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 | +41,163 | $3.79 | $156K | 351,055 |
| 2025-11-24 | Mazumdar Claire Chief Executive Officer | Sale 10b5-1 | −41,163 | $18.86 | $776K | 309,892 |
| 2025-11-24 | Mazumdar Claire Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −41,163 | 236,107 |
Page 8 of 14 · 276 trades